- Home
- SSSS vs PLX Comparison
SSSS vs PLX Comparison
Compare SSSS & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSSS
- PLX
- Stock Information
- Founded
- SSSS 2010
- PLX 1993
- Country
- SSSS United States
- PLX United States
- Employees
- SSSS N/A
- PLX N/A
- Industry
- SSSS Finance: Consumer Services
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SSSS Finance
- PLX Health Care
- Exchange
- SSSS Nasdaq
- PLX Nasdaq
- Market Cap
- SSSS 138.2M
- PLX 127.4M
- IPO Year
- SSSS N/A
- PLX 1998
- Fundamental
- Price
- SSSS $8.27
- PLX $1.45
- Analyst Decision
- SSSS Strong Buy
- PLX Strong Buy
- Analyst Count
- SSSS 4
- PLX 1
- Target Price
- SSSS $9.50
- PLX $15.00
- AVG Volume (30 Days)
- SSSS 202.2K
- PLX 620.4K
- Earning Date
- SSSS 08-11-2025
- PLX 08-13-2025
- Dividend Yield
- SSSS 12.09%
- PLX N/A
- EPS Growth
- SSSS N/A
- PLX N/A
- EPS
- SSSS N/A
- PLX 0.05
- Revenue
- SSSS $3,644,430.00
- PLX $59,764,000.00
- Revenue This Year
- SSSS $6.95
- PLX $65.02
- Revenue Next Year
- SSSS N/A
- PLX $57.34
- P/E Ratio
- SSSS N/A
- PLX $30.11
- Revenue Growth
- SSSS N/A
- PLX 0.18
- 52 Week Low
- SSSS $3.52
- PLX $0.82
- 52 Week High
- SSSS $9.12
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- SSSS 50.46
- PLX 44.75
- Support Level
- SSSS $8.18
- PLX $1.46
- Resistance Level
- SSSS $8.70
- PLX $1.53
- Average True Range (ATR)
- SSSS 0.32
- PLX 0.07
- MACD
- SSSS -0.10
- PLX 0.00
- Stochastic Oscillator
- SSSS 14.14
- PLX 32.14
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.